Patents Examined by Sabiha N. Qazi
  • Patent number: 11191835
    Abstract: The present disclosure relates to novel chlorin-vitamin conjugates and method of making and using the chlorin-vitamin conjugates.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: December 7, 2021
    Assignee: Purdue Research Foundation
    Inventor: Meden Fruel Isaac-Lam
  • Patent number: 11173146
    Abstract: Benzoxazole and indole type KCa3.1 activators as well as the therapeutic uses of such compounds in human or animal subjects and their use in ex vivo preservation of organs or tissues.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: November 16, 2021
    Assignee: The Regents of the University of California
    Inventors: Heike Wulff, Nichole Coleman, Brandon M. Brown, Aida Olivan-Viguera, Ralf Kohler
  • Patent number: 11103514
    Abstract: The present invention resides in the discovery that glucocorticoid receptor antagonists are effective for treating muscular dystrophy including type 1 or type 2 myotonic dystrophy. Treatment methods and kits are provided.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: August 31, 2021
    Assignee: Corcept Therapeutics, Inc.
    Inventor: Joseph Belanoff
  • Patent number: 11098021
    Abstract: Described herein are phenylsulfonamido-benzofuran derivatives, and pharmaceutically acceptable salts thereof. Also provided are pharmaceutical compositions, methods, uses, and kits involving compounds of Formulae (I), (II), (III), (IV), (V), or (VI) for treating and/or preventing proliferative diseases (e.g. cancers, inflammatory diseases, and autoimmune diseases) in a subject. The compounds and pharmaceutical compositions as described herein inhibit at least one protein of the BCL-2 family in a biological sample or subject to treat and/or prevent a proliferative disease. In certain embodiments, compounds described herein are selective inhibitors of MCL-1, a BCL-2 family member protein.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: August 24, 2021
    Assignees: Memorial Sloan-Kettering Cancer Center, Albert Einstein College of Medicine, Inc.
    Inventors: Emily H. Cheng, Paul Jeng, Ouathek Ouerfelli, James Hsieh, Guangli Yang, Evripidis Gavathiotis
  • Patent number: 11084793
    Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: August 10, 2021
    Assignee: Celgene Quanticel Research, Inc.
    Inventors: Young K. Chen, Toufike Kanouni, Stephen W. Kaldor, Jeffrey Alan Stafford, James Marvin Veal
  • Patent number: 11083702
    Abstract: Methods of treating propionic acidemia (PA), methylmalonic acidemia (MMA) and fatty acid oxidation disorders are described. The methods include administering an anaplerotic agent that can directly enter the tricarboxylic acid cycle, such as a succinate derivative or pro-drug, for example trisuccinylglycerol (TSG). Methods of restoring tricarboxylic acid (TCA) cycle function in a cell deficient for propionyl-CoA carboxylase (PCC) or methylmalonyl-CoA mutase (MUT) by contacting the cell with a succinate derivative or pro-drug, such as TSG, are also described.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: August 10, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Gerard Vockley, Al-Walid A. Mohsen
  • Patent number: 11059800
    Abstract: The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: July 13, 2021
    Assignees: Universidad Tecnica Particular De Loja, Cornell University, BioVentures, LLC
    Inventors: Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, Peter Crooks
  • Patent number: 11045441
    Abstract: Described is a method of inhibiting central apnea, central hypopnea or obstructive sleep apnea in a mammal. The method includes the step of administering to a mammal a central apnea inhibitory-effective, central hypopnea inhibitory-effective or obstructive sleep apnea inhibitory-effective amount of a composition comprising at least one retinoid or retinoid or retinoic acid receptor agonist.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: June 29, 2021
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Tracy Lee Baker, Gordon Mitchell, Daryl Fields
  • Patent number: 11045455
    Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: June 29, 2021
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Yinong Xie, Zejin You, Zhiwen Deng, Jun Zhu, Ao Wang, Yan Feng, Dong Long, Hong Zeng, Hongmei Song, Qijun Ye, Wei Qi, Donghai Su, Lichun Wang, Jingyi Wang
  • Patent number: 11013235
    Abstract: The following invention discloses a method for the control of plant diseases wherein a composition comprising a compound having the structure represented by one of the formulas from I to V, is applied to the plants. It also discloses the use of said compounds, or their salts for the stimulation of the natural defense and the induction of resistance against plant diseases. Moreover, it comprises the use of said compounds of structure represented by one of the formulas from I to V for the preventive or curative treatment of said diseases. A composition for agriculture, comprising a compound having the structure represented by one of the formulas from I to V, is also part of the invention.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: May 25, 2021
    Assignee: Centro de Ingeniería Genética y Biotecnología
    Inventors: Osmany Guirola Cruz, Orlando Borrás Hidalgo, Luis Javier González López, Raimundo Ubieta Gómez, Eulogio Pimentel Vázquez, Merardo Pujol Ferrer
  • Patent number: 11007160
    Abstract: This invention relates to methods of treating or preventing viral infections caused by flaviviruses, such as dengue virus, yellow fever virus, West Nile virus or Japanese encephalitis virus or infections caused by Chikungunya virus (CHIKV). The methods involve the administration of retinoic acid analogues to subjects who have, are suspected of having a flavivirus infection or infection with CHIKV, or to those who are at risk of becoming infected with a flavivirus or becoming infected with CHIKV.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: May 18, 2021
    Assignee: Monash University
    Inventors: Johanna Elisabeth Fraser, David Andrew Jans, Kylie Michelle Wagstaff
  • Patent number: 10993438
    Abstract: The following invention discloses a method for the control of plant diseases wherein a composition comprising a compound having the structure represented by one of the formulas from I to V, is applied to the plants. It also discloses the use of said compounds, or their salts for the stimulation of the natural defense and the induction of resistance against plant diseases. Moreover, it comprises the use of said compounds of structure represented by one of the formulas from I to V for the preventive or curative treatment of said diseases. A composition for agriculture, comprising a compound having the structure represented by one of the formulas from I to V, is also part of the invention.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: May 4, 2021
    Assignee: Centro de Ingeniería Genética y Biotecnología
    Inventors: Osmany Guirola Cruz, Orlando Borrás Hidalgo, Luis Javier González López, Raimundo Ubieta Gómez, Eulogio Pimentel Vázquez, Merardo Pujol Ferrer
  • Patent number: 10980231
    Abstract: Provided is an insect repellent having excellent repellency and being highly safe. An insect repellent comprising, as an active ingredient, at least one selected from the group consisting of 2-methoxy-4-propylphenol, ethyl 2-cyclohexylpropionate, ethyl phenylacetate, 2,4,6-trimethyl-3-cyclohexene-1-methanol, 9-decen-1-ol, 1-octen-3-ol, 1-decanol, ethyl 2-ethylhexanoate, and trans-2-hexenyl acetate.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: April 20, 2021
    Assignee: Kao Corporation
    Inventor: Takao Nakagawa
  • Patent number: 10975035
    Abstract: Disclosed herein are compounds of Formulae (I) and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 13, 2021
    Assignee: Recurium IP Holdings, LLC
    Inventors: Kevin Duane Bunker, Chuangxing Guo, Mark Charles Grier, Chad Daniel Hopkins, Joseph Robert Pinchman, Deborah Helen Slee, Peter Qinhua Huang, Mehmet Kahraman
  • Patent number: 10973829
    Abstract: The present invention relates to a combination treatment which comprises (a) at least one ERK inhibitor preferably Compound B as described herein, and (b) a c-RAF inhibitor or a pharmaceutically acceptable salt thereof, preferably Compound A, which may be combined into a single pharmaceutical composition or prepared for separate or sequential administration. It includes a c-RAF inhibitor and an ERK inhibitor prepared for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly an advanced solid tumor that harbors a Mitogen-activated protein kinase (MAPK) alteration, and includes methods of using these compounds in combination as well as a commercial package comprising such combination.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: April 13, 2021
    Assignee: NOVARTIS AG
    Inventors: Giordano Caponigro, Vesselina Cooke, Matthew John Meyer, Darrin Stuart
  • Patent number: 10945950
    Abstract: The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: March 16, 2021
    Assignee: VERONA PHARMA PLC
    Inventors: Peter Lionel Spargo, Edward James French, Phillip A. Haywood
  • Patent number: 10919929
    Abstract: The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: February 16, 2021
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Vivek Arora, Charles L. Sawyers, Michael J. Evans, Darren R. Veach
  • Patent number: 10894034
    Abstract: Compounds and methods involving inhibition of the enzymatic activity of QSOX1 (FIG. 13). The compounds and methods can be used in treatment of neoplastic cells, for example, to suppress tumor growth and invasion in a variety of cancers, including but not limited to myeloma and cancers of the breast, kidney, and pancreas.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: January 19, 2021
    Assignees: Arizona Board of Regents on behalf of Arizona State University, Mayo Foundation for Medical Education and Research
    Inventors: Douglas Lake, Erik Castle, Paul Hanavan, Douglas Faigel, Thai Ho
  • Patent number: 10893675
    Abstract: The present invention relates to a powder formulation comprising at least one insect repellent and magnesium hydroxide carbonate, and to a process for the preparation of the formulation and to the use of the formulation for repelling insects.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 19, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Termer, Frank Pfluecker, Lilia Heider, Alexandra Axt-Heidemann, Jutta Zur Lage
  • Patent number: 10889612
    Abstract: The present invention pertains to pharmaceutical chemical field, and relates to a sterol derivative as well as preparation method and uses thereof. Specifically, the present invention relates to a compound of Formula I, or a pharmaceutically acceptable salt, ester or ether thereof, wherein, R1 is selected from the group consisting of —OH, ?O(carbonyl), H, and C1-C3 alkyl; R2 is selected from the group consisting of —OH, H, and C1-C3 alkyl; R3 is selected from the group consisting of —OH, ?O, H, and C1-C3 alkyl; R4 is selected from the group consisting of —OH, H, and C1-C3 alkyl; and none, one, two, three or four of R1, R2, R3, and R4 are —OH. The compound of the present invention can inhibit HMG-CoA reductase, tumor cells and lipase effectively, and is a potential drug for reducing blood-fat, antitumors, or for losing weight.
    Type: Grant
    Filed: December 25, 2012
    Date of Patent: January 12, 2021
    Assignee: Beijing Peking University WBL Biotech Co., Ltd.
    Inventors: Zhenwen Duan, Shuren Guo, Xuemei Li